Canaccord Genuity Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target reduced by equities researchers at Canaccord Genuity Group from $128.00 to $79.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price objective points to a potential upside of 286.18% from the company’s previous close.

A number of other research analysts also recently issued reports on RARE. HC Wainwright decreased their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. TD Cowen decreased their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Barclays lowered their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Bank of America reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Finally, Robert W. Baird lowered their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.29.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.28 on Wednesday, reaching $20.46. The company had a trading volume of 1,248,854 shares, compared to its average volume of 2,733,294. The firm’s 50 day moving average price is $26.27 and its two-hundred day moving average price is $29.66. Ultragenyx Pharmaceutical has a 52-week low of $18.41 and a 52-week high of $45.00. The firm has a market cap of $1.97 billion, a PE ratio of -3.50 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.00 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 566.58%. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.39) EPS. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the sale, the chief financial officer owned 88,935 shares in the company, valued at $2,095,308.60. The trade was a 3.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 6,227 shares of company stock worth $187,126 in the last quarter. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $35,765,000. Hsbc Holdings PLC grew its stake in Ultragenyx Pharmaceutical by 88.6% during the 2nd quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 45,665 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in Ultragenyx Pharmaceutical by 108.1% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 35,185 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in Ultragenyx Pharmaceutical by 49.3% in the second quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after buying an additional 325,000 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Ultragenyx Pharmaceutical by 27.2% in the second quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after buying an additional 71,888 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating on RARE while lowering its price target from $60 to $50, signaling continued analyst conviction in the company’s longer-term upside despite the cut. HC Wainwright lowers price target
• Neutral Sentiment: Wedbush reiterated a “neutral” rating with a $25 price target, reflecting more cautious near-term expectations from another sell‑side shop. Wedbush reaffirms neutral
• Negative Sentiment: A large group of plaintiffs’ law firms have filed or are soliciting investors to join class actions alleging securities fraud for purchases between Aug. 3, 2023 and Dec. 26, 2025; lead‑plaintiff appointment deadlines (April 6, 2026) and multiple firms’ notices increase the likelihood of consolidated litigation, discovery and potential damages exposure that could pressure the stock. Representative notices include Robbins LLP, Bronstein Gewirtz & Grossman, Berger Montague, Levi & Korsinsky and others. Robbins LLP class action notice Bronstein Gewirtz class action notice Berger Montague class action notice

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.